Diagnostic relevance of plasma DNA and DNA integrity for breast cancer

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1183-1191

  Stötzer, Oliver J ^a   Lehner, Julia ^b   Fersching Gierlich, Debora ^b   Nagel, Dorothea ^b   Holdenrieder, Stefan ^c  

^a Hematology/Oncology Outpatient Center Munich   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Breast cancer; DNA integrity; Neoadjuvant chemotherapy; Plasma DNA

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA FRAGMENT; REPETITIVE DNA; TUMOR MARKER;

ALU SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA INTEGRATION; DNA INTEGRITY INDEX; DNA ISOLATION; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ADULT; ALU ELEMENTS; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; DNA; DNA FRAGMENTATION; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS;

EID: 84899069346     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1158-4     Document Type: Article

References (31)

1. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24(26):4270-6. (Pubitemid 46630784)
2. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6):1062-9. (Pubitemid 43794418)
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-92. (Pubitemid 41549890)
5. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27(4A): 1963-8. (Pubitemid 46954709)
6. Stieber P LD, Heinemann V, Untch M, Kahlert S, Nagel D. Kinetics of CEA and CA 15-3 correlate with response in patients undergoing chemotherapy for metastatic breast cancer. J Clin Oncol, ASCO Annual Meeting Proceedings. 2007;25((S18):):1087.
7. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11-79. (Pubitemid 352777353)
8. Chiu TW, Young R, Chan LY, Burd A, Lo DY. Plasma cell-free DNA as an indicator of severity of injury in burn patients. Clin Chem Lab Med. 2006;44(1):13-7. (Pubitemid 43010638)
9. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med. 2003;31(7):1947-51. (Pubitemid 36900748)
10. Lam NY, Rainer TH, Wong LK, Lam W, Lo YM. Plasma DNA as a prognostic marker for stroke patients with negative neuroimaging within the first 24 h of symptom onset. Resuscitation. 2006;68(1):71-8. (Pubitemid 43053370)
11. Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Schoenermarck U, Zachoval R, et al. Nucleosomal DNA fragments in autoimmune diseases. Ann N YAcad Sci. 2006;1075:318-27. (Pubitemid 44532800)
12. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci. 2009;46(1):1-24.
13. Holdenrieder S, Burges A, Reich O, Spelsberg FW, Stieber P. DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N YAcad Sci. 2008;1137:162-70.
14. Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci. 2008;1137:171-4.
15. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer. 2004;90(6):1211-5. (Pubitemid 38496815)
16. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res. 2002;8(12):3761-6. (Pubitemid 35424767)
17. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426-37.
18. Gu Z, Wang H, Nekrutenko A, Li WH. Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence. Gene. 2000;259(1-2):81-8. (Pubitemid 32119239)
19. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17(1):89-97. (Pubitemid 28293013)
20. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659-65. (Pubitemid 34292602)
21. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139-63. (Pubitemid 41351311)
22. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63(14):3966-8. (Pubitemid 36917913)
23. Ellinger J, Wittkamp V, Albers P, Perabo FG, Mueller SC, von Ruecker A, et al. Cell-free circulating DNA: Diagnostic value in patients with testicular germ cell cancer. J Urol. 2009;181(1):363-71.
24. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(18 Pt 1):5981-7. (Pubitemid 39287502)
25. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer. 2009;8: 105.
26. Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008;27(8):415-21.
27. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin Chim Acta. 2010;411(21-22):1611-24.
28. Boddy JL, Gal S, Malone PR, Shaida N, Wainscoat JS, Harris AL. The role of cell-free DNA size distribution in the management of prostate cancer. Oncol Res. 2006;16(1):35-41. (Pubitemid 44195048)
29. Schmidt B, Weickmann S, Witt C, Fleischhacker M. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci. 2008;1137:207-13.
30. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002;94(22): 1697-703. (Pubitemid 35446838)
31. de Kok JB, Hendriks JC, van Solinge WW, Willems HL, Mensink EJ, Swinkels DW. Use of real-time quantitative PCR to compare DNA isolation methods. Clin Chem. 1998;44(10):2201-4. (Pubitemid 28447074)